Cell Therapy News & Insights | RoslinCT

RoslinCT and BlueRock Therapeutics Partner to Expand Access to Clinical-Grade Pluripotent Cell Lines for Cell Therapy Developers

Cell and Gene Therapy, Cell Therapy, cGMP Manufacturing, Partnerships, Tech Transfer

July 08, 2026

RoslinCT and BlueRock Therapeutics Partner to Expand Access to Clinical-Grade Pluripotent Cell Lines for Cell Therapy Developers

RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta

Cell and Gene Therapy, Cell Therapy, cGMP Manufacturing, Partnerships, Tech Transfer

January 07, 2026

RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta

RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge® (omidubicel-only) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)

Cell and Gene Therapy, Cell Therapy, cGMP Manufacturing, Partnerships, Tech Transfer

December 16, 2025

RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge® (omidubicel-only) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)

RoslinCT and Lykan Bioscience Announce the Addition of Six <small>c</small>GMP Suites to Meet Growing Demand

Leadership, New cGMP suites, Partnerships, Site Expansion

February 23, 2023

RoslinCT and Lykan Bioscience Announce the Addition of Six cGMP Suites to Meet Growing Demand

RoslinCT and Lykan Bioscience Announce the Appointment of Dr. Michael Mendicino to its Scientific Advisory Board

Leadership, Partnerships, Scientific Advisor

January 10, 2023

RoslinCT and Lykan Bioscience Announce the Appointment of Dr. Michael Mendicino to its Scientific Advisory Board

RoslinCT and Lykan Bioscience Announce the Establishment of a Scientific Advisory Board

Leadership, Partnerships

September 12, 2022

RoslinCT and Lykan Bioscience Announce the Establishment of a Scientific Advisory Board

RoslinCT and Lykan Bioscience Combine to Create Leading Advanced Cell Therapy CDMO

Leadership, Partnerships

August 04, 2022

RoslinCT and Lykan Bioscience Combine to Create Leading Advanced Cell Therapy CDMO

GHO Capital invests in RoslinCT, a leading cell therapy CDMO

Cell Therapy, Investment, Partnerships

January 11, 2022

GHO Capital invests in RoslinCT, a leading cell therapy CDMO